Nektar Therapeutics (NKTR) Stock Forecast: StockMap's 2-Week Call
NKTR stock forecast: StockMap's model leans Underperform on Nektar Therapeutics for the two weeks after the Nov 13 close, toward NKTR trailing the growth index. It is a lean inside the no-call band, not a call, and not a price target. Right in 2 of 3 two-week windows on NKTR since Sep 24; by chance, a call on the same dates was right 51% of the time.
Nektar Therapeutics last closed at $37.27, +0.05% on the session.
Against the IVW growth benchmark the position is +0.96% over the forecast window.
Nektar Therapeutics' market cap is $1.27B as of November 13, 2026.
Leans down ↘: a small lean, not a call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -42 (too close to call).
Where NKTR sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 3 bullish and 12 bearish.
Agreement across those insights is 80%.
27 daily calls for NKTR so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks Nektar Therapeutics in the 24th percentile on return on equity, where 100 is best.
Nektar Therapeutics is classified under Health Care / Biotechnology.
StockMap tracks Nektar Therapeutics as the 122nd largest of the 391 companies it covers in the Biotechnology industry, part of the Health Care sector.
Across that group the current two-week reads are 186 Moderate Underperform, 157 Neutral, 33 Strong Underperform and 15 Moderate Outperform.
On that composite Nektar Therapeutics ranks 325th of 391 in the group, against a group median of -0.24.